Vaccine Development Global Program

Developing new, affordable vaccines for the people who need them most

Vaccines are one of the most effective, affordable, and beneficial tools in public health. Because market forces alone are not always strong enough to drive the development of vaccines most urgently needed in lower-income countries, PATH’s Vaccine Development Global Program is stepping in to fill the gap. Find out more »

New fact sheets and a journal supplement on rotavirus

Baby receiving an oral vaccine

Photo credit: PATH/Mike Wang

We recently updated two fact sheets that summarize our work on rotavirus vaccines. One provides a general summary (PDF), while the other shares a more technical perspective (PDF). In addition, the journal Vaccine has published a new open-access supplement on rotavirus in India. It includes more than 30 articles covering a range of issues, including disease burden, epidemiology, and research on vaccines. Read the supplement »


blog: Start planning your Global Handwashing Day celebration for Oct. 15 »

website: Visit the new website for PATH’s Better Immunization Data Initiative »

survey: Help PATH identify the global health innovations that have the most promise to accelerate progress »

newsletter: View the latest issue of VAC’s quarterly e-newsletter »

website: Check out PATH’s new online portal for global health advocacy »

Sign up for our e-newsletter

Our e-newsletter, Vaccines for the Future, provides quarterly updates on our efforts to develop innovative, safe, effective, and affordable vaccines. It includes updates on our progress, partnerships, and specific activities. Sign up now »

Visit the Vaccine Resource Library

PATH’s Vaccine Resource Library (VRL) seeks to gather the world’s best immunization resources in a single, easy-to-use website. The VRL offers high-quality, scientifically accurate documents and links on specific diseases and topics in immunization. Learn more »

Banner photos, clockwise from left: PATH/Gabe Bienczycki; PATH/Chutima Suraratdecha; PATH.

Comments are closed.